Maastricht Delphi consensus on event definitions for classification of recurrence in breast cancer research

Journal of the National Cancer Institute

Volumn 106, Issue 12, 2014, Pages

  Moossdorff, Martine ^a   Van Roozendaal, Lori M ^b   Strobbe, Luc J A ^c   Aebi, Stefan ^d   Cameron, David A ^e   Dixon, J Michael ^f   Giuliano, Armando E ^g   Haffty, Bruce G ^h   Hickey, Brigid E ⁱ   Hudis, Clifford A ^j   Klimberg, V Suzanne ^k   Koczwara, Bogda ^l   Kühn, Thorsten ^m   Lippman, Marc E ⁿ   Lucci, Anthony ^p   Piccart, Martine ^q   Smith, Benjamin D ^o   Tjan Heijnen, Vivianne C G ^a   Van De Velde, Cornelis J H ^r   Van Zee, Kimberly J ^s   Vermorken, Jan B ^t   Viale, Giuseppe ^u   Voogd, Adri C ^a   Wapnir, Irene L ^v   White, Julia R ^w   Smidt, Marjolein L ^a   more..

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c CANISIUS WILHELMINA HOSPITAL   (Netherlands)

^d LUZERNER KANTONSSPITAL   (Switzerland)

^e UNIVERSITY OF EDINBURGH   (United Kingdom)

^f WESTERN GENERAL HOSPITAL   (United Kingdom)

^g CEDARS SINAI MEDICAL CENTER   (United States)

^h RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

ⁱ PRINCESS ALEXANDRA HOSPITAL   (Australia)

^j WEILL CORNELL MEDICAL COLLEGE   (United States)

^k UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^l FLINDERS UNIVERSITY   (Australia)

^m KLINIKUM ESSLINGEN   (Germany)

ⁿ UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^o UNIVERSITY OF TEXAS   (United States)

^p UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^q JULES BORDET INSTITUTE   (Belgium)

^r LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^s MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^t ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^u UNIVERSITY OF MILAN   (Italy)

^v STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^w OHIO STATE UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BREAST CANCER; CANCER CLASSIFICATION; CANCER RESEARCH; CONSENSUS; DELPHI STUDY; FEMALE; HUMAN; INTRADUCTAL CARCINOMA; LYMPH NODE; MALE; MEDICAL EXPERT; METASTASIS; PRIORITY JOURNAL; QUESTIONNAIRE; SKIN; STERNUM; SUBCUTANEOUS TISSUE; THORAX WALL; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CONSENSUS DEVELOPMENT; INTERNATIONAL COOPERATION; LYMPH NODE METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, SECOND PRIMARY; PATHOLOGY; SECONDARY; SKIN TUMOR;

BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; DELPHI TECHNIQUE; FEMALE; HUMANS; INTERNATIONAL COOPERATION; LYMPHATIC METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, SECOND PRIMARY; QUESTIONNAIRES; SKIN NEOPLASMS; THORACIC WALL;

EID: 84922393869     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/dju288     Document Type: Article

References (12)

1. Mathoulin-Pelissier S, Gourgou-Bourgade S, Bonnetain F, Kramar A. Survival End Point Reporting in Randomized Cancer Clinical Trials: A Review of Major Journals. J Clin Oncol. 2008;26(22):3721-3726.
2. Meropol NJ. Comparative Effectiveness Research to Inform Medical Decisions: The Need for Common Language. J Clin Oncol. 2012;30(34):4192-4193.
3. Cuzick J. Primary endpoints for randomised trials of cancer therapy. Lancet. 2008;371(9631):2156-2158.
4. Nout RA, Fiets WE, Struikmans H, et al. The in- or exclusion of nonbreast cancer related death and contralateral breast cancer significantly affects estimated outcome probability in early breast cancer. Breast Cancer Res Treat. 2008;109(3):567-572.
5. Fumagalli D, Bedard PL, Nahleh Z, et al. A common language in neoadjuvant breast cancer clinical trials: proposals for standard definitions and endpoints. Lancet Oncol. 2012;13(6):e240-e248.
6. Hudis CA, Barlow WE, Costantino JP, et al. Proposal for Standardized Definitions for Efficacy End Points in Adjuvant Breast Cancer Trials: The STEEP System. J Clin Oncol. 2007;25(15):2127-2132.
7. Montori VM, Permanyer-Miralda G, Ferreira-Gonzalez I, et al. Validity of composite end points in clinical trials. BMJ. 2005;330(7491):594-596.
8. Fitch K, Bernstein SJ, Aguilar MS, et al. The RAND/UCLA Appropriateness Method User's Manual. Santa Monica, CA: RAND; 2001.
9. Fink A, Kosecoff J, Chassin M, Brook RH. Consensus methods: characteristics and guidelines for use. Am J Public Health. 1984;74(9):979-983.
10. Jones J, Hunter D. Consensus methods for medical and health services research. BMJ. 1995;311(7001):376-380.
11. Linstone HA, Turoff M. The Delphi method: techniques and applications: Addison-Wesley Pub. Co., Advanced Book Program; 1975.
12. Bellera CA, Pulido M, Gourgou S, et al. Protocol of the Definition for the Assessment of Time-to-event Endpoints in CANcer trials (DATECAN) project: Formal consensus method for the development of guidelines for standardised time-to-event endpoints' definitions in cancer clinical trials. Eur J Cancer. 2013;49(4):769-781.